Dergiler / Türk Üroloji Dergisi/Turkish Journal of Urology / 2014 / Cilt: 40 - Sayı: 3

The treatment of late-onset hypogonadism

Sayfa
170–179
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The purpose of this review is to discuss what is known and what remains unclear with respect to the benefts and risks of testosterone replacement treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Late-onset hypogonadism (LOH) in aging men is a clinical and biochemical syndrome caused by an age-re - lated decline in testosterone.
📊
Temel Bulgular & Veri:Until such evidence is available, testosterone treatment should be restricted to elderly men with very low testosterone levels in the presence of clinical symptoms, and the advantages and disadvantages need to be accurately assessed.
💡
Sonuç & Katkı:The purpose of this review is to discuss what is known and what remains unclear with respect to the benefts and risks of testosterone replacement treatment.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Late-onset hypogonadism (LOH) in aging men is a clinical and biochemical syndrome caused by an age-re - lated decline in testosterone. Despite published in guidelines and recommendations, uncertainty surrounds the profle of clinical symptoms as well as the biochemical threshold of diagnosis. The only evidence-based treatment of late-onset hypogonadism is testosterone replacement therapy. The actual available evidence of the long-term risks and outcomes of testosterone-replacement therapy remains very limited, and care - fully designed placebo-controlled trials of testosterone administration to assess the risks and benefts of such a therapy are required. Until such evidence is available, testosterone treatment should be restricted to elderly men with very low testosterone levels in the presence of clinical symptoms, and the advantages and disadvantages need to be accurately assessed. Careful monitoring of potential side effects is necessary. The purpose of this review is to discuss what is known and what remains unclear with respect to the benefts and risks of testosterone replacement treatment.

🔖

Bu Makaleye Atıf Yap

ÜÇER, O., GÜMÜŞ, B. H. (2014). The treatment of late-onset hypogonadism. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 40 - Sayı: 3, 170–179. https://ajindex.com/articles/328026

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment, and monitoring of lateonset hypogonadism in males: ISA, ISSAM, and EAU recommen- dations. J Androl 2006
  2. [CrossRef] 2. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJi et al. International Society of Andrology (ISA)
  3. International Society for the Study of the Aging Male (ISSAM)
  4. European Association of Urology (EAU): Investigation, treatment, and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005
  5. [CrossRef] 3. Ucer O, Gumus B, Okur M, Karatas TC, Buyuksu C. Does Late- Onset Hypogonadism Occur by Aging? The Evaluation of IIEF, Ams-Q and Biochemical Parameters. Turkiye Klinikleri J Med Sci 2010
  6. [CrossRef] 4. Mäkinen JI, Huhtaniemi I. Androgen replacement therapy in late- onset hypogonadism: current concepts and controversies - a mini- review. Gerontology 2011
  7. [CrossRef] 5. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011
  8. [CrossRef] 6. Feldman HA, Longcope C, Derby C, Johannes C, Araujo AB, Coviello A, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002
  9. [CrossRef] 7. Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Biol 2003
  10. [CrossRef] 8. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinol- ogy of aging. Science 1997
  11. [CrossRef] 9. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late- onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASArecommendations. Eur Urol 2009
  12. [CrossRef] 10. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005
  13. [CrossRef] 11. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: a User’s Manual, Revised 2nd Printing Boston MA (USA): The Health Institute, New England Medical Center, 1994. 12. Lee DM, O’Neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, et al. The European Male Aging Study (EMAS): design, methods and recruitment. Int J Androl 2009
  14. [CrossRef] 13. Morley JE, Charlton E, Patrick P, Kai